Marksans Pharma is a global manufacturer of store-brand and own-label medicines - the company behind the painkillers, cough syrups and allergy tablets on the shelves of Walmart, Boots and Woolworths that carry the retailer’s name, not a big pharma logo. It began in 2001 as a subsidiary of Glenmark, was spun off and renamed within two years, and has since transformed from a contract research shop into a fully integrated business that controls every step from molecule development in its own labs to the finished bottle on a supermarket shelf. The recurring approach is simple: buy or build a front-end sales operation in a tightly regulated market - the US, the UK, Australia - and feed it from low-cost Indian factories, cutting out middlemen and capturing the margin at both ends.
Business segments
Three engines, one manufacturing backbone - a dominant US over-the-counter business built on retailer partnerships, a UK and European platform that is the country’s largest private-label cough-liquid maker, and a smaller Australian and emerging-markets presence, all supplied by four factories that turn out 26 billion pills, capsules and liquids a year.
1. US over-the-counter formulations: the store-brand engine behind America’s pharmacy shelves
Marksans is a preferred low-cost manufacturing partner for the private-label painkillers, allergy meds and digestive remedies sold by Walmart, CVS, Walgreens and Target - it competes on price and reliability, not on consumer advertising.
- Paid per unit, not per brand - the company manufactures tablets, softgels, liquids and ointments and sells them to retailers and wholesalers on a per-unit basis; roughly three-quarters of its US revenue comes from OTC products, with the remainder from prescription generics.
- Softgel know-how keeps rivals out - the Goa factory holds one of the few USFDA approvals held by an Indian company for generic soft gelatin capsules, a dosage form with high barriers to entry because of tricky formulation chemistry and steep capital costs; the US softgel market alone is worth about USD 9 billion.
- Made in America, too - its Farmingdale, New York plant (Time Cap Labs) can produce 6 billion tablets and hard capsules a year and carries a “Made in the USA” label, while ANDA-approved prescription products are exported from India; the US facility passed its last FDA inspection with no 483s issued.
- A pipeline of 51 products waiting to launch - the company had over 200 products in development as of FY26, with 51 earmarked specifically for the US and North America, and plans to add 20-25 new products every year.
2. UK and Europe: the pharmacy’s own-label supplier and the NHS’s generics partner
Through two subsidiaries - Bell for OTC and Relonchem for prescription drugs - Marksans is a top-5 Indian pharma company in the UK, supplying own-label medicines to every major supermarket and pharmacy chain as well as the National Health Service.
- The UK’s biggest private-label cough-liquid factory - Bell, Sons & Co. in Southport makes over 450 SKUs and is the country’s largest manufacturer of retailer-branded and branded cough liquids, with 90% of its revenue from the UK and the rest exported to West Africa and the Middle East.
- 100% reach within the distribution channel - the company’s products reach every corner of the UK pharmacy and grocery channel, with customers including Tesco, ASDA, Morrisons, Boots and Lloyds; Relonchem holds more than 160 product licences and distributes its own-label Rx portfolio through the same network.
- A new front door into Europe - in June 2026 Marksans bought QliniQ, a Dutch pharmaceutical distributor with its own EU-licensed warehouse, a direct-to-customer webshop, and established relationships with Dutch wholesalers, pharmacies and health insurers; the acquisition gives it a ready-made route into continental Europe’s insurer-led tender channels.
3. Australia, New Zealand and emerging markets: a beachhead built on branded generics
A 60%-owned Australian subsidiary, Nova Pharmaceuticals, has been selling branded generic and private-label analgesics and antifungals to Australian retailers since 2006, while a Dubai-based unit opens the door to the Middle East.
- Shelf space at Woolworths and Coles - Nova supplies top Australian retailers and pharmacies including Woolworths, Coles, Aldi and Metcash, and also fields a specialty salesforce for hospitals and mass-market OTC.
- No factory of its own - Nova sources all its products from Marksans’ Indian and UK plants, so every sale flows manufacturing margin back to the parent.
- A derma-focused entry into Dubai - Access Healthcare, acquired in 2022, supplies dermatology products through the Dubai Health Authority and gives the company a foothold in the MENA region.
Manufacturing and R&D backbone
Four factories on three continents, accredited by every major Western regulator, turn out 26 billion doses a year - and four in-house R&D centres keep the product pipeline stocked.
- R&D spends to build a moat - the company invested INR 89 crore in R&D in FY26 (3% of revenue), filed over 500 dossiers, and holds more than 300 approved ANDAs and marketing authorisations; its scientists focus on extended-release technologies and softgel delivery systems that are harder for competitors to copy.
- Backward integration into raw materials - Marksans is building its own API (active pharmaceutical ingredient) capacity for captive consumption of its top molecules, aiming to insulate itself from Chinese supply-chain swings and capture the full value chain from raw chemical to finished box.
Group structure and partners
A net-cash Indian parent with no joint ventures controls wholly-owned operating subsidiaries in every major market, each holding the local licences and customer relationships that make the forward-integration model work.
- UK: two operating arms under one holding company - Marksans Pharma (UK) Limited owns Bell, Sons & Co. (OTC, 450+ SKUs) and Relonchem (Rx, 175+ marketing authorisations), which share a distribution network to reach every UK pharmacy.
- US: Time Cap Labs at the centre - Marksans Pharma Inc. owns Time Cap Laboratories, the Farmingdale manufacturer, along with smaller entities for real estate and branded OTC marketing.
- Australia: a 60% stake held since 2005 - Nova Pharmaceuticals Australasia is the only subsidiary with a non-controlling interest (40%), and it acts as the front end for Australia and New Zealand.
- New European vehicles - wholly-owned subsidiaries were incorporated in Germany, Ireland and Canada in FY26, and the Dutch acquisition QliniQ B.V. (bought for €7.5 million in cash) adds an EU-licensed wholesaler with €9.35 million in revenue and zero debt.
- INR 990 crore in cash and an AA- credit rating - the group has been net cash positive for more than five years, giving it a war chest for further front-end acquisitions without stretching the balance sheet.